Two Sigma Investments LP Acquires 71,575 Shares of Dynavax Technologies Co. (NASDAQ:DVAX)

Two Sigma Investments LP increased its position in Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 9.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 866,356 shares of the biopharmaceutical company's stock after purchasing an additional 71,575 shares during the period. Two Sigma Investments LP owned 0.66% of Dynavax Technologies worth $11,063,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. E Fund Management Co. Ltd. grew its stake in Dynavax Technologies by 4.6% in the fourth quarter. E Fund Management Co. Ltd. now owns 17,627 shares of the biopharmaceutical company's stock worth $225,000 after purchasing an additional 771 shares during the period. Summit Investment Advisors Inc. grew its stake in Dynavax Technologies by 7.0% in the fourth quarter. Summit Investment Advisors Inc. now owns 13,782 shares of the biopharmaceutical company's stock worth $176,000 after purchasing an additional 904 shares during the period. Nisa Investment Advisors LLC grew its stake in Dynavax Technologies by 19.8% in the fourth quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company's stock worth $83,000 after purchasing an additional 1,076 shares during the period. Sanctuary Advisors LLC grew its stake in Dynavax Technologies by 6.3% in the fourth quarter. Sanctuary Advisors LLC now owns 18,836 shares of the biopharmaceutical company's stock worth $245,000 after purchasing an additional 1,109 shares during the period. Finally, Russell Investments Group Ltd. grew its stake in Dynavax Technologies by 96.5% in the fourth quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company's stock worth $30,000 after purchasing an additional 1,169 shares during the period. 96.96% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on DVAX. William Blair reaffirmed an "outperform" rating on shares of Dynavax Technologies in a research note on Friday, February 21st. Wall Street Zen downgraded Dynavax Technologies from a "buy" rating to a "hold" rating in a report on Tuesday, May 6th. The Goldman Sachs Group dropped their target price on Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating on the stock in a report on Thursday, April 17th. JMP Securities dropped their target price on Dynavax Technologies from $33.00 to $31.00 and set a "market outperform" rating on the stock in a report on Wednesday, May 7th. Finally, HC Wainwright reissued a "buy" rating and issued a $31.00 target price on shares of Dynavax Technologies in a report on Friday, February 21st. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, Dynavax Technologies currently has a consensus rating of "Hold" and an average price target of $24.00.

Dynavax Technologies Stock Up 2.6%

Dynavax Technologies stock traded up $0.25 during mid-day trading on Thursday, hitting $9.75. The company had a trading volume of 619,652 shares, compared to its average volume of 2,210,128. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33. The stock's 50 day moving average price is $11.16 and its two-hundred day moving average price is $12.38. Dynavax Technologies Co. has a 12 month low of $9.22 and a 12 month high of $14.63. The company has a market capitalization of $1.17 billion, a PE ratio of 54.37 and a beta of 1.26.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.03 by ($0.14). The business had revenue of $68.16 million for the quarter, compared to the consensus estimate of $70.01 million. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. As a group, sell-side analysts anticipate that Dynavax Technologies Co. will post 0.32 earnings per share for the current fiscal year.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.